Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Candel Therapeutics stock

Learn how to easily invest in Candel Therapeutics stock.

Candel Therapeutics is a biotechnology business based in the US. Candel Therapeutics shares (CADL) are listed on the NASDAQ and all prices are listed in US Dollars. Candel Therapeutics employs 65 staff and has a trailing 12-month revenue of around $125,000.

How to buy Candel Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – CADL. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Candel Therapeutics stock price (NASDAQ: CADL)

Use our graph to track the performance of CADL stocks over time.

Candel Therapeutics shares at a glance

Information last updated 2023-01-19.
Latest market close$2.36
52-week range$1.40 - $6.75
50-day moving average $1.80
200-day moving average $3.06
Wall St. target price$11.60
PE ratio 75.0033
Dividend yield $0 (0%)
Earnings per share (TTM) $0.03

Buy Candel Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Candel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Candel Therapeutics price performance over time

Historical closes compared with the close of $2.355 from 2023-01-25

1 week (2023-01-19) 4.67%
1 month (2022-12-27) 59.12%
3 months (2022-10-27) 17.75%
6 months (2022-07-27) -30.74%
1 year (2022-01-27) -51.04%
2 years (2021-01-23) N/A
3 years (2020-01-23) N/A
5 years (2018-01-23) N/A

Is Candel Therapeutics stock undervalued or overvalued?

Valuing Candel Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Candel Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Candel Therapeutics's P/E ratio

Candel Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 75x. In other words, Candel Therapeutics shares trade at around 75x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Candel Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Candel Therapeutics financials

    Revenue TTM $125,000
    Gross profit TTM $125,000
    Return on assets TTM -23.35%
    Return on equity TTM -21.05%
    Profit margin 0%
    Book value $1.80
    Market capitalisation $65 million

    TTM: trailing 12 months

    Candel Therapeutics share dividends

    We're not expecting Candel Therapeutics to pay a dividend over the next 12 months.

    Candel Therapeutics overview

    Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc.

    Frequently asked questions

    What percentage of Candel Therapeutics is owned by insiders or institutions?
    Currently 34.624% of Candel Therapeutics shares are held by insiders and 21.825% by institutions.
    How many people work for Candel Therapeutics?
    Latest data suggests 65 work at Candel Therapeutics.
    When does the fiscal year end for Candel Therapeutics?
    Candel Therapeutics's fiscal year ends in December.
    Where is Candel Therapeutics based?
    Candel Therapeutics's address is: 117 Kendrick Street, Needham, MA, United States, 02494
    What is Candel Therapeutics's ISIN number?
    Candel Therapeutics's international securities identification number is: US1374041093

    More guides on Finder

    Ask an Expert

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site